Preimplantation Genetic Testing Market Size and Share Analysis - Growth Trends and Forecasts (2026-2033)

Market Size and Trends

The Preimplantation Genetic Testing market is estimated to be valued at USD 2.5 billion in 2026 and is expected to reach USD 5.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.8% from 2026 to 2033. This significant growth underscores increasing adoption of advanced reproductive technologies and rising awareness among prospective parents about genetic screening, driving demand across both developed and emerging markets.

Key trends shaping the Preimplantation Genetic Testing market include advancements in genetic sequencing technologies and the integration of AI-driven analytics, which enhance the accuracy and efficiency of testing processes. Additionally, increasing government initiatives promoting fertility treatments and growing investments in R&D are expanding the scope of genetic testing applications. These developments, combined with rising infertility rates and greater consumer focus on personalized medicine, are propelling market growth globally.

Segmental Analysis:

By Test Type: Preimplantation Genetic Diagnosis Leading Due to Precision and Clinical Impact

In terms of By Test Type, Preimplantation Genetic Diagnosis (PGD) contributes the highest share of the market owing to its critical role in detecting specific genetic disorders before embryo implantation. PGD's ability to identify single-gene mutations and inherited diseases provides prospective parents with crucial information, enabling the selection of embryos free from targeted genetic conditions. This precise diagnostic capability is particularly impactful for couples with a known family history of genetic disorders or previous pregnancy losses due to genetic abnormalities. Furthermore, advancements in PGD techniques have enhanced its accuracy and reduced turnaround time, making it more accessible for routine use in assisted reproductive technology (ART) cycles. The growing awareness among patients and fertility specialists about the benefits of avoiding genetic diseases has driven the adoption of PGD. The clinical trust in PGD also stems from its well-established protocols and regulatory acceptance in many regions, supporting confident decision-making during in vitro fertilization (IVF) procedures. Additionally, the emotional and financial burden associated with genetic conditions motivates patients to seek the most reliable test available, positioning PGD as the preferred choice. The integration of PGD with other genomic technologies further broadens its application scope, enhancing its appeal within the preimplantation genetic testing landscape.

By Technology: Next-Generation Sequencing Dominates Through Enhanced Accuracy and Comprehensive Analysis

By Technology, Next-Generation Sequencing (NGS) holds the highest market share due to its superior analytical capabilities compared to traditional methods. NGS provides a comprehensive and high-resolution view of the embryo's genetic makeup, enabling simultaneous screening of multiple genes and chromosomal abnormalities with unprecedented detail and sensitivity. The technology's ability to analyze the entire genome rapidly accelerates the diagnosis process, reducing waiting times for patients and clinics. Moreover, NGS significantly improves the detection of aneuploidies and mosaicism, which are critical factors in identifying viable embryos and enhancing IVF success rates. Its multiplexing advantage allows the processing of numerous samples in a single run, resulting in cost efficiencies and scalability. The continuous improvements in bioinformatics tools and data interpretation algorithms have further increased the reliability and clinical utility of NGS, encouraging widespread adoption across fertility centers. NGS also facilitates the integration of preimplantation genetic screening and diagnosis within a single workflow, streamlining clinical practice. Importantly, as the technology advances, the reduction in sequencing costs reinforces its position as the preferred technology platform in the preimplantation genetic testing market. This convergence of accuracy, speed, and affordability makes NGS the cornerstone of modern genetic testing in reproductive medicine.

By End User: Fertility Clinics Lead Owing to Increasing IVF Treatments and Personalized Care

In terms of By End User, Fertility Clinics account for the largest share of the market, primarily driven by the rising number of in vitro fertilization (IVF) procedures and a growing focus on personalized reproductive care. Fertility clinics serve as the primary interface for couples seeking assisted reproduction and preimplantation genetic testing, integrating these tests seamlessly into their workflows to improve pregnancy outcomes. The increasing incidence of infertility and delayed parenthood globally has expanded the patient pool seeking fertility treatments, thereby fueling demand within these clinics. Additionally, fertility clinics are investing heavily in advanced infrastructure and skilled personnel, enabling them to incorporate sophisticated genetic testing technologies like PGD and NGS into their service offerings. The clinics' commitment to providing individualized embryo selection strategies underlines their role in optimizing live birth rates and minimizing miscarriage risks. Collaborations between fertility clinics and diagnostic laboratories further enhance accessibility and turnaround times, reinforcing clinics as pivotal consumers of preimplantation genetic testing. Patient preference for consolidated care and counseling in a single location strengthens fertility clinics' dominance. The ability of clinics to participate in research and clinical trials also contributes to innovation adoption and service improvement, sustaining their leadership in this end user segment.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Preimplantation Genetic Testing (PGT) market is driven by a well-established healthcare infrastructure, advanced research capabilities, and substantial investment in reproductive technologies. The presence of leading fertility clinics and genetic testing companies, coupled with supportive government policies that encourage innovation and accessibility, bolster the market's leadership. The region's ecosystem benefits from widespread insurance coverage for assisted reproductive technologies in certain parts, as well as extensive awareness and acceptance of genetic screening. Key players such as Illumina, CooperSurgical, and Invitae have substantial operations here, contributing innovative PGT solutions and forging partnerships that enhance service reach and technological capabilities.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth, fueled by increasing infertility awareness, rising disposable incomes, and expanding healthcare infrastructure. Government initiatives aimed at improving maternal and child health, along with favorable regulatory reforms, are accelerating the adoption of advanced reproductive technologies, including PGT. The region's diverse population with rising demand for personalized medicine also plays a pivotal role. Furthermore, strategic collaborations between international diagnostic firms and regional healthcare providers are expanding service accessibility. Notable players such as BGI Genomics, Genesis Genetics, and MedGenome are actively expanding their footprint, leveraging local expertise and technological advancements to capture emerging market opportunities.

Preimplantation Genetic Testing Market Outlook for Key Countries

United States

The United States' market benefits from its position at the forefront of medical technology innovation and regulatory support that facilitates rapid clinical adoption of new genetic testing methodologies. Leading companies including CooperSurgical and Invitae have introduced a broad range of PGT products, from PGT-A (aneuploidy) to PGT-M (monogenic diseases), supported by extensive clinical trials and collaborations with fertility centers. High consumer awareness and insurance reimbursements in select states further stimulate market demand.

China

China's rapidly growing fertility market is characterized by government policies that promote healthcare modernization and increased funding for reproductive health initiatives. Providers like BGI Genomics capitalize on the country's large patient base, offering next-generation sequencing-based PGT solutions. Partnerships with hospitals and reproductive centers reinforce service penetration, while regulatory adaptations are increasingly favorable for genetic testing innovation, making China a key hub in the Asia Pacific PGT market.

United Kingdom

The United Kingdom continues to lead in Europe, supported by the National Health Service (NHS) and a strong framework for genetic research and ethics oversight. Companies such as Oxford Gene Technology and Igenomix UK have established robust networks with IVF clinics, allowing for comprehensive PGT services within public and private healthcare sectors. The UK's emphasis on stringent quality standards and regulatory compliance ensures high confidence among practitioners and patients.

India

India's market is expanding rapidly due to rising fertility issues, growing medical tourism, and government reforms promoting access to advanced diagnostic services. Local companies like MedGenome and international firms collaborate extensively to provide cost-effective and culturally tailored PGT testing. Infrastructure development coupled with increasing patient awareness supports the expanding adoption of PGT across metropolitan and tier-2 cities.

Germany

Germany's well-developed healthcare system and emphasis on precision medicine foster a mature PGT market within Europe. Leading players such as LifeCodexx and Genoma contribute advanced genetic screening tests integrated into fertility treatment protocols. The country's stringent data protection and regulatory environment also ensure that patient confidentiality and ethical considerations are maintained, reinforcing trust and market stability.

Market Report Scope

Market Segmentation

Test Type Insights (Revenue, USD, 2021 - 2033)

• Preimplantation Genetic Diagnosis (PGD)
• Preimplantation Genetic Screening (PGS)
• Comprehensive Chromosome Screening (CCS)
• Others

Technology Insights (Revenue, USD, 2021 - 2033)

• Next-Generation Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Polymerase Chain Reaction (PCR)
• Microarray

End User Insights (Revenue, USD, 2021 - 2033)

• Fertility Clinics
• Diagnostic Laboratories
• Hospitals
• Research Institutes
• Others

Regional Insights (Revenue, USD, 2021 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• CooperSurgical
• Illumina, Inc.
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.
• Vitrolife AB
• F. Hoffmann-La Roche AG
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories
• Natera, Inc.
• Invitae Corporation
• Bioneer Corporation
• Genea Biomedx
• CooperGenomics